The MINIject MIGS device has been approved in Europe for patients with open-angle glaucoma, according to a press release from iSTAR Medical.
In four trials in more than 150 patients, the device has demonstrated sustained IOP reduction and a positive safety profile.
“With today’s European approval, MINIject becomes the only commercially available MIGS device targeting the supraciliary space as a natural outflow pathway for IOP reduction,” Michel Vanbrabant, CEO of iSTAR Medical, said in the release.
The device is being rolled out in select regions across Europe, and the first